SCHEMBL1624464

SCHEMBL1624464

C[C@H](NC(=O)CN)C(=O)N1CCC(C(=O)c2cccc(C(=N)N)c2)(c2ccccc2)[C@@]1(C(=O)O)c1ccc2ccccc2c1

nearest known ligand 0.35

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
PLG P00747 12/20 0.35
F10 P00742 5/20 0.35
HPN P05981 4/20 0.35
PLAU P00749 4/20 0.35
F12 P00748 3/20 0.35
KLKB1 P03952 3/20 0.35
PROC P04070 3/20 0.35
ST14 Q9Y5Y6 2/20 0.35
HGFAC Q04756 1/20 0.35
F2 P00734 1/20 0.34
PRSS1 P07477 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1624134 0.93 HPN (0.35) PLGF10HPNPLAUF12
SCHEMBL6972729 0.84 F10 (0.38) F10F2PRSS1
SCHEMBL6982269 0.84 F10 (0.38) F10F2PRSS1
SCHEMBL8117786 0.69 HTRA1 (0.39)
SCHEMBL1624971 0.65 F2 (0.37) PLGF10HPNPLAUF12
SCHEMBL1625141 0.59 F10 (0.43) F10PLAUF2PRSS1
SCHEMBL1623653 0.59 F10 (0.43) F10PLAUF2PRSS1
SCHEMBL29941285 0.58 CYP2C9 (0.47)
SCHEMBL1625170 0.58 PLAU (0.41) F10PLAUF2PRSS1
SCHEMBL1622580 0.57 PLAU (0.39) F10PLAUF2PRSS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7928137-B2 Meta-benzamidine derivatives as serine protease inhibitors TULARIK LIMITED (GB) 2011-04-19 US disclosed
US-20070155790-A1 Meta-benzamidine derivatives as serine protease inhibitors LIEBESCHUETZ JOHN W 2007-07-05 US disclosed
US-7220781-B2 Meta-benzamidine derivatives as serine protease inhibitors TULARIK LIMITED (GB) 2007-05-22 US disclosed
EP-1009758-B1 META-BENZAMIDINE DERIVATIVES AS SERINE PROTEASE INHIBITORS TULARIK LTD (GB) 2005-06-01 EP disclosed
US-20040143018-A1 Meta-benzamidine derivatives as serine protease inhibitors LIEBESCHUETZ JOHN WALTER (GB) 2004-07-22 US disclosed
US-6740682-B2 TREATMENT OF THROMBOTIC DISEASES, ASTHMA, EMPHYSEMA, CIRRHOSIS, ARTHRITIS, CARCINOMA, MELANOMA, RESTENOIS, ATHEROMA, TRAUMA, SHOCK AND REPERFUSION INJURY. TULARIK LIMITED (GB) 2004-05-25 US disclosed
US-20020055522-A1 Meta-benzamidine derivatives as serine protease inhibitors TULARIK LIMITED (GB) 2002-05-09 US disclosed
EP-1009758-A1 META-BENZAMIDINE DERIVATIVES AS SERINE PROTEASE INHIBITORS Protherics Molecular Design Limited (GB) 2000-06-21 EP disclosed
WO-1999011658-A1 META-BENZAMIDINE DERIVATIVES AS SERIN PROTEASE INHIBITORS PROTEUS MOLECULAR DESIGN LTD. (GB) 1999-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020055522-A1 Meta-benzamidine derivatives as serine protease inhibitors SERPINE1, PEPD, PRSS1 PLG 65/4885F10 378/4885HPN 4/4885
US-20070155790-A1 Meta-benzamidine derivatives as serine protease inhibitors PEPD, SERPINE1, HPN PLG 46/4885F10 292/4885HPN 3/4885
US-20040143018-A1 Meta-benzamidine derivatives as serine protease inhibitors SERPINE1, PEPD, PRSS1 PLG 65/4885F10 378/4885HPN 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.